Prometheus Laboratories (@prometheuslab) header
Prometheus Laboratories (@prometheuslab) profile picture

A leader of precision healthcare in gastroenterology, offering novel diagnostic testing services to help physicians provide the highest level of patient care

San Diego, CA
Joined April 2021
Photo by Prometheus Laboratories (@prometheuslab)Photo by Prometheus Laboratories (@prometheuslab)Photo by Prometheus Laboratories (@prometheuslab)Photo by Prometheus Laboratories (@prometheuslab)Photo by Prometheus Laboratories (@prometheuslab)Photo by Prometheus Laboratories (@prometheuslab)Photo by Prometheus Laboratories (@prometheuslab)Photo by Prometheus Laboratories (@prometheuslab)Photo by Prometheus Laboratories (@prometheuslab)Photo by Prometheus Laboratories (@prometheuslab)
As treatment options have been introduced for MASH, identifying treatment-eligible patients has become an increasingly important aspect of MASH management. Providers face a new challenge: determining which patients may be eligible for treatment and when intervention may be appropriate. MASH Precis™ was purpose-built to identify treatment-eligible F2-F3 patients and support next-step assessment decisions. Learn more: prometheuslabs.com/disease-t… #MASH #MASLD #LiverDisease #Hepatology
1
Looking back on #TLM26, one topic was at the center of our conversations: how to effectively identify and assess patients with MASH in an evolving therapeutic landscape. We were proud to showcase MASH Precis™, our non-invasive blood-based test designed to support fibrosis staging and help identify treatment-eligible patients. By combining objective fibrosis staging, prognostic risk assessment and biomarker insights in a single test, MASH Precis provides actionable information to support clinical decision-making. Thank you to everyone who visited the Prometheus Laboratories booth, met with our clinical team and shared their perspectives. We appreciate the opportunity to engage with the liver disease community and look forward to continuing the conversation. #Gastroenterology #MASH #MASLD #LiverFibrosis #Hepatology #GI #Diagnostics
1
50
Three clinically relevant insights. One blood draw. MASH Precis combines: ✅Objective fibrosis staging ✅ Prognostic assessment with the ELF® Risk Score ✅Biomarker-level insights MASH Precis is a non-invasive test that aids in identifying treatment-eligible MASH patients to help providers make more informed decisions throughout the patient evaluation process. Stop by booth 2268 at The Liver Meeting or visit our website to learn more: prometheuslabs.com/disease-t… #TLM26 #Gastroenterology #MASH #MASLD #LiverFibrosis #Hepatology #GI #Diagnostics
23
Healthcare organizations are increasingly looking for scalable approaches to liver fibrosis assessment that can fit into routine clinical workflows. MASH Precis was designed to fit into emerging MASH assessment pathways with a simple blood draw. One potential pathway: ➡️FIB-4 identifies elevated risk ➡️ MASH Precis aids in fibrosis staging and risk assessment ➡️Results support referral and treatment evaluation decisions Stop by booth 2268 at The Liver Meeting or visit our website to learn more: prometheuslabs.com/disease-t… #TLM26 #Gastroenterology #MASH #MASLD #LiverFibrosis #Hepatology #GI #Diagnostics
18
New research demonstrates the MASH Precis™ Fibrosis Score improved identification of treatment-eligible F2-F3 MASH patients while reducing uncertainty in fibrosis staging. We're sharing the data at The Liver Meeting today, November 6, in the poster hall. The authors will be at the poster to answer questions from 1:00 pm - 2:00 pm. If you're attending, stop by and see poster 2304, “MASH Precis Fibrosis Score: Development, Validation, and Head-to-Head Comparison with ELF for F2-F3 Treatment-Eligible Patient Selection in Biopsy-Proven MASH.” Read the full announcement: prometheuslabs.com/research-… #TLM26 #Gastroenterology #MASH #MASLD #LiverFibrosis #Hepatology #GI #Diagnostics
29
Prometheus Laboratories is exhibiting at The Liver Meeting 2026! Visit us at Booth 2268 to learn about our newest non-invasive blood test that aids in identifying treatment-eligible F2-F3 MASH patients. We still have meeting times available – contact your local representative or send us a message here to get on our calendar. #TLM26 #Gastroenterology #MASH #MASLD #LiverFibrosis #Hepatology #GI #Diagnostics
21
MASLD, formerly known as NAFLD, is the most common chronic liver disease around the world, affecting more than 30% of the global population. Yet millions remain undiagnosed, highlighting the urgent need for earlier detection and diagnosis before the disease silently progresses. #LiverHealth #MASLD #MASH #MetabolicHealth #HealthcareEducation
14
Thank you to everyone who came by our booth at #NASPGHAN2026 to discuss how our portfolio of diagnostic tests can aid in the diagnosis of IBD and optimization of therapy for improved pediatric patient outcomes. We’ll see you next year in Nashville! #NASPGHAN2026 #Gastroenterology #PediatricGI #CrohnsDisease #UlcerativeColitis #IBD #GI #Diagnostics
17
When should clinicians begin assessing infliximab therapy? A recent pediatric IBD study found that patients monitored during induction achieved clinical remission sooner than those first monitored during maintenance therapy. Read it here: academic.oup.com/crohnscolit… These findings suggest that earlier assessment during induction may provide valuable insights that may help inform important dosing decisions. Visit NASPGHAN Booth 513 to learn more about precision-guided dosing during induction with PredictrPK IFX. #PediatricGI #IBD #CrohnsDisease #UlcerativeColitis #NASPGHAN2026
1
25
For many pediatric patients with moderate-to-severe IBD, factors such as disease burden, drug clearance and individual variability can influence infliximab dosing decisions. That's why there is growing interest in precision-guided dosing approaches that can help support informed and individualized treatment decisions throughout the IBD patient journey. Visit Booth 513 to learn more about precision-guided dosing with PredictrPK. #PediatricGI #IBD #CrohnsDisease #UlcerativeColitis #NASPGHAN2026
15
Two pediatric patients can present with similar symptoms, similar endoscopic findings and even similar diagnoses, yet their disease can progress very differently. Understanding which patients may be at greater risk for a more complicated disease course remains one of the biggest challenges in IBD management. To address this challenge, there is growing interest in approaches that provide additional insights into factors that may influence disease course and treatment outcomes, which may help inform personalized patient care. If you're attending NASPGHAN, stop by Booth 513 to learn how personalized diagnostics are helping to advance pediatric IBD management. #PediatricGI #IBD #CrohnsDisease #UlcerativeColitis #NASPGHAN2026
15
Many non-invasive tests were developed to assess advanced fibrosis. MASH Precis was purpose-built to help identify treatment-eligible F2-F3 patients, addressing an emerging need in the therapeutic era of MASH management. Visit our website to learn more about MASH Precis: prometheuslabs.com/disease-t… #MASH #MASLD #LiverHealth #Hepatology #PrecisionDiagnostics
21
Prometheus Laboratories will be exhibiting at NASPGHAN 2026 in San Diego! Visit us at Booth 513 to learn about our non-invasive diagnostic tests for pediatric IBD patients. We still have meeting times available too – contact your local representative or send us a message here to get on our calendar. #NASPGHAN2026 #Gastroenterology #MASH #MASLD #IBD #GI #Diagnostics
17
Looking back on #ACG2026, one theme stood out: the growing need for practical, scalable approaches for fibrosis assessment and patient evaluation in the therapeutic era of MASH. We were proud to introduce MASH Precis™, our new non-invasive test designed to support fibrosis staging and help identify treatment-eligible patients with MASH. By combining objective fibrosis staging, prognostic risk assessment and biomarker insights in a single blood-based test, MASH Precis provides actionable information to support patient management decisions. Thank you to everyone who visited the Prometheus Laboratories booth and shared their perspectives. We appreciated the opportunity to connect with so many clinicians committed to advancing care in liver disease and IBD, and we look forward to continuing those conversations. #ACG2026 #Gastroenterology #MASH #MASLD #IBD #GI #Diagnostics
30
With IBD patients experiencing an average 16-month delay from symptom onset to diagnosis, clinicians need tools that can help reduce diagnostic uncertainty and support more informed decision-making. At #ACG2026, we're highlighting IBD Precis, an advanced serology test designed to provide greater clarity in IBD identification, disease differentiation and risk stratification. Visit us in booth 900 to see how today's serology is helping shape more personalized IBD care. #IBD #ACG2026 #Gastroenterology #PrecisionMedicine
30
🚀 Introducing MASH Precis™ As the therapeutic era of MASH evolves, healthcare organizations face a growing need for practical, scalable approaches to fibrosis assessment and patient evaluation. MASH Precis is a purpose-built, blood-based test designed to help identify treatment-eligible F2-F3 MASH patients while providing objective fibrosis staging, prognostic risk assessment and biomarker insights from a single blood draw. Learn more about how MASH Precis can support emerging MASH assessment pathways: prometheuslabs.com/launches-… And if you’re at ACG, stop by booth 900 today to learn more. #MASH #LiverDisease #Hepatology #Diagnostics #PrecisionMedicine #ACG2026
31
One of the limitations of therapeutic drug monitoring is timing, as clinicians often need to wait until trough to obtain data. For patients receiving ustekinumab that may mean waiting up to 8 weeks. In a prospective IBD study, investigators evaluated whether clearance-based mid-cycle pharmacokinetic (PK) assessment could provide insights into disease control before the end of the dosing interval. Findings suggest optimal pharmacokinetic profiles were associated with higher clinical and biochemical remission rates. We're sharing these data at ACG today, October 12, in the poster hall. If you're attending, stop by and see poster 3410, “Clearance-Based Modeling to Predict Ustekinumab Trough Levels and Disease Control in Inflammatory Bowel Disease.” #ACG2026 #IBD #InflammatoryBowelDisease #ustekinumab #biologics
25
Prometheus Laboratories is exhibiting at ACG 2026! Visit us at Booth 900 to learn about our newest non-invasive blood tests for MASH and IBD patients. We still have meeting times available – contact your local representative or send us a message here to get on our calendar. #ACG2026 #Gastroenterology #MASH #MASLD #IBD #GI #Diagnostics
18
“Expanding access to Anser® IFX testing for subcutaneous infliximab enables clinicians to make informed decisions and aligns with our mission to help our patients achieve treatment goals in a timely and accessible manner.” - Bincy Abraham, MD, MS, Director of the Underwood Center - Fondren Inflammatory Bowel Disease Program Learn about the Celltrion Testing Access Program: prometheuslabs.com/scifx
28
❓What if vedolizumab trough levels alone aren’t the best signal of remission? A new real‑world pharmacokinetic study suggests vedolizumab clearance may be a stronger predictor of clinical and endoscopic remission in IBD than trough concentration alone. Key takeaways: ✅Higher VDZ clearance = lower odds of remission ✅ Prior anti‑TNF exposure ↑ clearance by ~26% This challenges how we think about VDZ monitoring and supports a shift toward model‑informed, exposure‑based decision‑making. 🔗Full text: mdpi.com/1999-4923/16/12/162… #IBD #Vedolizumab #PrecisionMedicine #Gastroenterology #Pharmacokinetics #InflammatoryBowelDisease #CrohnsDisease #Crohns #Colitis
31